Caris Collaboration to Identify Eligible Participants for NCI-MATCH Trial
Caris Life Sciences is collaborating with the National Cancer Institute (NCI) to identify patients eligible to participate in the Phase 2 NCI-MATCH (Molecular Analysis for Therapy Choice) study,…